Reference 2019-556

REF:           2019-556

Subject:       Chronic lymphocytic leukaemia

    

 

Request:

  1. Over the past 6 months [latest possible], how many chronic lymphocytic leukaemia (CLL) patients have you treated?

If possible, how many CLL patients treated were new to therapy in the past 3 months?

 

  1. How many chronic lymphocytic leukaemia patients, have been treated in the past 6 months with the following;
  • Fludarabine (Fludara), cyclophosphamide (Cytoxan), and rituximab (known as FCR)
  • Bendamustine and rituximab (known as BR)
  • Ibrutinib [Imbruvica]
  • Chlorambucil
  • Venetoclax
  • Obinutuzumab
  • Idelalisib
  • Fludarabine and rituximab (known as FR)
  • High-dose prednisone and rituximab
  • Pentostatin (Nipent), cyclophosphamide, and rituximab (known as PCR)
  • Alemtuzumab (Campath) with rituximab

 

 

Response:

There have been no chronic lymphocytic leukaemia (CLL –  ICD 10 code C91.1) patients treated at Bolton between 1/3/19 and 31/8/2019.